AUSTIN, Texas, May 7, 2019 /PRNewswire/ -- VolitionRx Limited
(NYSE AMERICAN: VNRX) ("Volition") today announced that it has
added to its extensive clinical trial program with the execution of
a contract under the previously announced Memorandum of
Understanding, to conduct its first large-scale lung cancer study
in conjunction with the prestigious National Taiwan University
("NTU"). The study will be conducted under the supervision of
Professor Chen Jin-Shing in the
Department of Surgery of NTU and will include 1,200 subjects
receiving Low-Dose Computed Tomography scans, including 1,000 with
lung cancer.
Professor Chen Jin-Shing
commented: "Lung cancer remains the deadliest of all the cancers
and there is a high unmet clinical need for either a non-invasive
early stage lung cancer detection test or for a triage test which
can improve the specificity of the Low-Dose CT scan currently used.
The early data from the Nu.Q™ technology platform is promising, and
clearly larger scale studies are required. We are delighted to
execute this agreement and very much look forward to evaluating the
Nu.Q™ technology platform".
"We are delighted with the progress we have achieved with the
network of key influencers and collaborators in Asia and in particular our expanded
relationship with the National Taiwan University," commented Dr.
Jasmine Kway, Chief Executive
Officer of Singapore Volition. "At a total cost of approximately
$320,000 payable over two years, this
study demonstrates once more Volition's commitment to conducting
large yet cost effective trials worldwide. We are hopeful that our
recent proof of concept results in lung cancer will be repeated in
this much larger cohort. We expect to release preliminary data
relating to the first 600 patient samples in the first quarter of
2020."
Volition recently announced preliminary results from two proof
of concept studies utilising its first optimized product-grade
assay:
- In a lung cancer cohort (76 subjects), a single Nu.Q™ assay
detected lung cancer, including stage I lung cancer. The Area Under
the Curve ("AUC") for this single assay was 85%, cancer versus
healthy.
- In a second confirmatory lung cancer cohort (152 subjects), the
same single Nu.Q™ assay also detected lung cancer with an AUC of
79%, cancer versus healthy.
Volition has also recently executed a nonbinding Memorandum of
Understanding with Shanghai Fosun Long March Medical Science Co.,
Ltd. with the shared intention to enter into a binding agreement
and to conduct three small-scale clinical trials in China. One of the trials is in lung cancer,
and the others are in colorectal cancer and ovarian cancer, with
preliminary data expected in 2019.
About the National Taiwan University
NTU is one of the most prestigious universities in the world and
is the top university in Taiwan.
The University has a wide network of partners and collaborators and
plays a leading role in education and research. The University has
four university level research centers, with an overall student
population of approximately 33,000.
About Volition
Volition is a multi-national life sciences company developing
simple, easy to use, cost effective blood tests to help diagnose a
range of cancers and other diseases. Early diagnosis has the
potential to not only prolong the life of patients, but also to
improve their quality of life. The tests are based on the science
of Nucleosomics™, which is the practice of identifying and
measuring nucleosomes in the bloodstream or other bodily fluid - an
indication that disease is present.
Volition's research and development activities are currently
centered in Belgium, with
additional offices in Texas,
London and Singapore, as the company focuses on bringing
its diagnostic products to market.
For more information about Volition, visit Volition's website
(http://www.volitionrx.com) or connect with us via:
Twitter: https://twitter.com/volitionrx
LinkedIn: https://www.linkedin.com/company/volitionrx
Facebook: https://www.facebook.com/VolitionRx/
YouTube: https://www.youtube.com/user/VolitionRx
The contents found at Volition's website address, Twitter,
LinkedIn, Facebook, and YouTube are not incorporated by reference
into this document and should not be considered part of this
document. The addresses for Volition's website, Twitter,
LinkedIn, Facebook, and YouTube are included in this document as
inactive textual references only.
Media / Investor Contacts
Louise Batchelor,
Volition
mediarelations@volitionrx.com
+44 (0)7557
774620
|
Scott Powell,
Volition
investorrelations@volitionrx.com
+1 (646) 650
1351
|
Joseph Green,
Edison Advisors
jgreen@edisongroup.com
+1 (646) 653
7030
|
|
Safe Harbor Statement
Statements in this press release may be "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, that concern matters that involve risks and
uncertainties that could cause actual results to differ materially
from those anticipated or projected in the forward-looking
statements. Words such as "expects," "anticipates," "intends,"
"plans," "aims," "targets," "believes," "seeks," "estimates,"
"optimizing," "potential," "goal," "suggests," "could," "would,"
"should," "may," "will" and similar expressions identify
forward-looking statements. These forward-looking statements relate
to the negotiation and execution of a binding agreement with Fosun
Long March Medical Science Co., Ltd. and the timing of availability
of preliminary data under such agreement, the effectiveness of
Volition's blood-based diagnostic tests as well as Volition's
ability to develop and successfully commercialize such test
platforms for early detection of cancer and other diseases.
Volition's actual results may differ materially from those
indicated in these forward-looking statements due to numerous risks
and uncertainties. For instance, if Volition fails to develop and
commercialize diagnostic products, it may be unable to execute its
plan of operations. Other risks and uncertainties include
Volition's failure to obtain necessary regulatory clearances or
approvals to distribute and market future products in the clinical
IVD market; a failure by the marketplace to accept the products in
Volition's development pipeline or any other diagnostic products
Volition might develop; Volition will face fierce competition and
Volition's intended products may become obsolete due to the highly
competitive nature of the diagnostics market and its rapid
technological change; and other risks identified in Volition's most
recent Annual Report on Form 10-K and Quarterly Reports on Form
10-Q, as well as other documents that Volition files with the
Securities and Exchange Commission. These statements are based on
current expectations, estimates and projections about Volition's
business based, in part, on assumptions made by management. These
statements are not guarantees of future performance and involve
risks, uncertainties and assumptions that are difficult to predict.
Forward-looking statements are made as of the date of this release,
and, except as required by law, Volition does not undertake an
obligation to update its forward-looking statements to reflect
future events or circumstances.
Nucleosomics™, and Nu.Q™ and their respective logos
are trademarks and/or service marks of VolitionRx Limited and its
subsidiaries. All other trademarks, service marks and trade names
referred to in this press release are the property of their
respective owners. Additionally, unless otherwise specified, all
references to "$" refer to the legal currency of the United States of America.
View original
content:http://www.prnewswire.com/news-releases/volitionrx-limited-executes-a-contract-for-clinical-trial-program-in-lung-cancer-300845164.html
SOURCE VolitionRx Ltd